Medicure Inc.

205 articles with Medicure Inc.

• Medicure Reports Financial Results for Quarter Ended March 31, 2021

  5/10/2021

  Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter ended March 31, 2021.

• Medicure Announces Resignation of Chief Financial Officer and Succession Plan

  4/28/2021

  Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported that after nearly 10 years with Medicure, Chief Financial Officer James Kinley is resigning, effective May 15, 2021, to pursue another business opportunity.

• Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020

  4/20/2021

   Medicure Inc. today reported its results from operations for the quarter and year ended December 31, 2020. 

• Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021

  3/30/2021

  Medicure Inc., announced that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 30, 2021 at 1:00 PM EST.

• Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, February 23, 2021

  2/22/2021

  Medicure Inc. (TSXV: MPH) (OTC: MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, February 23, 2021 at 12:00 PM EST

• Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021

  2/4/2021

  - Medicure Inc.(TSXV:MPH) (OTC:MCUJF), announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 8, 2021 at 2:00 PM EST ( 1:00 PM CST , 12:00 PM MST ).

• Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT

  1/27/2021

  Medicure Inc. (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT ®  

• Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency

  1/7/2021

  Medicure Inc., a cardiovascular pharmaceutical company, announced that through its Barbados subsidiary, Medicure International Inc., it intends to file an Investigational New Drug application with the U.S. Food and Drug Administration pertaining to its legacy product Pyridoxal 5′-phosphate for the treatment of seizures associated with pyridoxine 5'-phosphate oxidase deficiency.

• Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug

  12/17/2020

  Medicure Inc. announced that Medicure Pharma Inc., it entered into a definitive agreement on December 15, 2020, to acquire 100% of Marley Drug, Inc, a leading specialty pharmacy serving more than 30,000 customers across the United States, from an arms-length third-party, for an upfront payment on closing of USD $6.3 million, subject to certain holdbacks, as well as additional payments based on future performance of Marley.

• Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.

  12/2/2020

  Medicure Inc. (" Medicure " or the " Company ") (TSXV: MPH) (OTC:MCUJF), a cardiovascular pharmaceutical company, today announces that it has retained the services of Renmark Financial Communications Inc. (" Renmark ") to condu

• Medicure Reports Financial Results for Quarter Ended September 30, 2020

  11/11/2020

  Medicure Inc.cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30 , 2020.  Quarter Ended September 30, 2020 Highlights:

• Medicure Q3 2020 Results and Conference Call Dates

  11/5/2020

  Medicure Inc., a cardiovascular pharmaceutical company, will release financial results for the quarter ended September 30, 2020 on Wednesday, November 11, 2020.

• Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar

  10/5/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the "Agreement") with Reliance Life Sciences Private Limited (&qu

• Medicure Announces AGGRASTAT Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

  8/24/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is reporting that early investigator sponsored clinical reports evaluating the efficacy of AGGRASTAT® (tirofiban hydrochloride) show promise for preventing and treating thrombotic complications due to COVID-19.

• Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement

  8/20/2020

  Medicure Inc. (" Medicure " or the " Company ") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. (" Sensible

• Medicure Reports Financial Results for Quarter Ended June 30, 2020

  8/11/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2020.

• Medicure Q2 2020 Results and Conference Call Dates

  8/5/2020

  Medicure Inc., a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020.

• Medicure Announces Normal Course Issuer Bid

  6/29/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted the Company's notice of intention to make a normal course issuer bid ("NCIB").

• Medicure Announces Positive Results for AGGRASTAT in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

  6/29/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

• Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG (Pitavastatin) Tablets

  6/25/2020

  Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH), (OTC:MCUJF), a pharmaceutical company, is pleased to announce the launch of a direct to patient online pharmacy program for the distribution of ZYPITAMAGTM in the United States.